Prosecution Insights
Last updated: May 29, 2026

Ocugen Inc.

5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
5
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
1
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 7 days (1)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
4
Medium (80%)
0
Easy (0%)
1
Unknown (20%)

Rejection Statute Mix

BucketCases
§103 only4 (80%)
No statute on record1 (20%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
60% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
2
Mechanical / Eng
40% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
PURDY, KYLE A 1 40.8% +36.8%
SCHERBEL, TODD J 1 76.2% +51.6%
BOECKELMAN, JACOB A 1 36.1% +46.3%
HOBAN, MELISSA A 1 63.0% +12.9%
REGLAS, GEORGIANA C 1 38.8% +30.2%

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
16973987 SCAFFOLD WITH ADHESIVE FOR ARTICULAR CARTILAGE REPAIR HOBAN, MELISSA A 25d overdue
18197692 METHOD FOR USE OF A DOUBLE-STRUCTURED TISSUE IMPLANT FOR TREATMENT OF TISSUE DEFECTS SCHERBEL, TODD J 9d overdue
18503177 Treatment of Neurological Disorder Using NHR PURDY, KYLE A 1d overdue
17668511 NEOCARTILAGE CONSTRUCTS USING UNIVERSAL CELLS BOECKELMAN, JACOB A 7d
17080078 ADENO-ASSOCIATED VIRUS VECTOR MEDIATED GENE THERAPY FOR OPHTHALMIC DISEASES REGLAS, GEORGIANA C 35d

Top Art Units

Art UnitApps
1611 1
3771 1
1655 1
3774 1
1651 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18503177 Treatment of Neurological Disorder Using NHR PURDY, KYLE A 1611 Other Non-Final OA 1d overdue Pending Nov 06, 2023
18197692 METHOD FOR USE OF A DOUBLE-STRUCTURED TISSUE IMPLANT FOR TREATMENT OF TISSUE DEFECTS SCHERBEL, TODD J 3771 §103 Non-Final OA 9d overdue Pending May 15, 2023
17668511 NEOCARTILAGE CONSTRUCTS USING UNIVERSAL CELLS BOECKELMAN, JACOB A 1655 §103 Non-Final OA 7d Pending Feb 10, 2022
16973987 SCAFFOLD WITH ADHESIVE FOR ARTICULAR CARTILAGE REPAIR HOBAN, MELISSA A 3774 §103 Non-Final OA 25d overdue Pending Dec 10, 2020
17080078 ADENO-ASSOCIATED VIRUS VECTOR MEDIATED GENE THERAPY FOR OPHTHALMIC DISEASES REGLAS, GEORGIANA C 1651 §103 Non-Final OA 35d Pending Oct 26, 2020

Managing Ocugen Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month